BioCentury
ARTICLE | Clinical News

Xerecept corticotropin releasing factor: Phase III started

August 29, 2005 7:00 AM UTC

NTII began an open-label, U.S. and Canadian Phase III trial to evaluate the extended use of Xerecept. The trial will enroll patients from 2 ongoing double-blind Phase III Xerecept trials, which are ex...